FDA Gives Clovis Oncology's Rubraca a Priority Review

Sales of Clovis Oncology's (NASDAQ: CLVS) Rubraca could get a big lift just in time for summer. Today, the company told investors a supplemental application that could expand the addressable patient population of its lead drug will get a speedy review.

In November, Clovis submitted an application to expand Rubraca's drug label to include prostate cancer patients with tumors driven by BRCA1/2 mutations. The U.S. Food and Drug Administration (FDA) has officially started reviewing the application and an approval decision is expected in May.

Image source: Getty Images.

Continue reading

Source Fool.com